Dublin, April 03, 2019 (GLOBE NEWSWIRE) -- The "Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2019" report has been added to ResearchAndMarkets.com's offering.
The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.
This report provides details of the latest collaborative R&D deals announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date with the latest information, the report provides details of collaborative R&D deals from 2014 to 2019.
There has been a long standing willingness for parties to enter collaborative R&D deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.
Collaborative R&D is a specific type of partnering deal whereby the parties to the deal agree to collaborate on the research and development and subsequently commercialize a compound, product or technology.
There are several forms of a collaborative R&D deal; A traditional collaborative R&D arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subsequent sales of product(s) derived from the intellectual property.
In more recent times, licensing is often the outcome of a successful period of collaborative R&D on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the collaborative R&D agreement governs who has permission to commercialize and what payments are due should commercialization proceed.
The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to commercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.
This report contains a comprehensive listing of all collaborative R&D deals announced since 2014 as recorded in the deals and alliances database, including financial terms where available, plus links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Key benefits
Report scope
Available deals and contracts are listed by:
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in collaborative R&D dealmaking
2.1. Introduction
2.2. Definition of collaborative R&D partnering
2.3. Success factors for collaborative R&D deals
2.4. When collaborative R&D can be useful
2.5. Attributes of collaborative R&D deals
2.6. Trends in collaborative R&D deals since 2014
2.6.1. Collaborative R&D dealmaking by year, 2014 to 2019
2.6.2. Collaborative R&D dealmaking by phase of development, 2014 to 2019
2.6.3. Collaborative R&D dealmaking by industry sector, 2014 to 2019
2.6.4. Collaborative R&D dealmaking by therapy area, 2014 to 2019
2.6.5. Collaborative R&D dealmaking by technology type, 2014 to 2019
2.6.6. Collaborative R&D dealmaking by most active company, 2014 to 2019
2.7. The future of collaborative R&D deals
Chapter 3 - Overview of collaborative R&D deal structure
3.1. Introduction
3.2. Pure versus multi-component collaborative R&D deals
3.3. Pure collaborative R&D agreement structure
3.3.1. Example collaborative R&D agreements
3.3.1.a. Case study 1: Marinus Pharmaceuticals - NovaMedica
3.3.1.b. Case study 2: Idenix Pharmaceuticals - Janssen Pharmaceuticals
3.4. Collaborative R&D as part of a wider alliance agreement
3.4.1. Example collaborative R&D agreements and their licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics - UniQure
3.4.1.b. Case study 4: Kyowa Hakko Kirin - Ultragenyx Pharmaceuticals
3.4.2. Example licensing option right clauses in collaborative R&D deals
3.4.2.a. Case study 5: Forest Laboratories - Trevena
3.4.2.b. Case study 6: Abbvie - Receptos
Chapter 4 - Leading collaborative R&D deals
4.1. Introduction
4.2. Top collaborative R&D deals by value
Chapter 5 - Top 50 most active collaborative R&D dealmakers
5.1. Introduction
5.2. Top 50 most active collaborative R&D dealmakers
Chapter 6 - Collaborative R&D deal term financials
6.1. Introduction
6.2. Collaborative R&D partnering headline values
6.3. Collaborative R&D deal upfront payments
6.4. Collaborative R&D deal milestone payments
6.5. Collaborative R&D royalty rates
Chapter 7 - Collaborative R&D contract directory 2014 - 2019
7.1. Introduction
7.2. Collaborative R&D deals with contracts 2014 to 2019
Appendices
Appendix 1 - Collaborative R&D dealmaking by companies A-Z
Appendix 2 - Collaborative R&D dealmaking by industry sector
Appendix 3 - Collaborative R&D dealmaking by stage of development
Appendix 4 - Collaborative R&D dealmaking by therapy area
Appendix 5 - Collaborative R&D dealmaking by technology type
For more information about this report visit https://www.researchandmarkets.com/research/tt9skp/global?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Biotechnology, Pharmaceuticals, Diagnostics